Skip to main content
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1986 Dec 13;293(6561):1529–1532. doi: 10.1136/bmj.293.6561.1529

Oral acyclovir in acute herpes zoster.

M W McKendrick, J I McGill, J E White, M J Wood
PMCID: PMC1342307  PMID: 3099943

Abstract

Oral acyclovir at a dose of 800 mg five times daily for seven days was compared with placebo in a randomised double blind trial conducted at three centres in the United Kingdom. The study group comprised 205 elderly immune competent patients suffering from herpes zoster who were entered within 72 hours of the onset of rash. Acyclovir significantly reduced the times to arrest of new lesion formation (p = 0.005), loss of vesicles (p less than 0.001), and full crusting (p = 0.02) in those patients entered within 48 hours of the onset of rash. In addition, there was a significant reduction in pain during treatment with acyclovir as compared with placebo (p = 0.008). Of the patients with severe pain on entry, 40% (10/25) of those treated with acyclovir had no or only mild pain at the end of treatment, whereas in the placebo group all had residual moderate or severe pain (p less than 0.001). No clinically important adverse effects of acyclovir were reported. Oral acyclovir may modify acute herpes zoster and reduce pain.

Full text

PDF
1529

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bean B., Braun C., Balfour H. H., Jr Acyclovir therapy for acute herpes zoster. Lancet. 1982 Jul 17;2(8290):118–121. doi: 10.1016/s0140-6736(82)91090-x. [DOI] [PubMed] [Google Scholar]
  2. ELLIOTT F. A. TREATMENT OF HERPES ZOSTER WITH HIGH DOSES OF PREDNISONE. Lancet. 1964 Sep 19;2(7360):610–611. doi: 10.1016/s0140-6736(64)90507-0. [DOI] [PubMed] [Google Scholar]
  3. Keczkes K., Basheer A. M. Do corticosteroids prevent post-herpetic neuralgia? Br J Dermatol. 1980 May;102(5):551–555. doi: 10.1111/j.1365-2133.1980.tb07654.x. [DOI] [PubMed] [Google Scholar]
  4. McGill J., MacDonald D. R., Fall C., McKendrick G. D., Copplestone A. Intravenous acyclovir in acute herpes zoster infection. J Infect. 1983 Mar;6(2):157–161. doi: 10.1016/s0163-4453(83)92787-1. [DOI] [PubMed] [Google Scholar]
  5. McGill J. Topical acyclovir in herpes zoster ocular involvement. Br J Ophthalmol. 1981 Aug;65(8):542–545. doi: 10.1136/bjo.65.8.542. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. McKendrick M. W., Care C., Burke C., Hickmott E., McKendrick G. D. Oral acyclovir in herpes zoster. J Antimicrob Chemother. 1984 Dec;14(6):661–665. doi: 10.1093/jac/14.6.661. [DOI] [PubMed] [Google Scholar]
  7. Peterslund N. A., Esmann V., Ipsen J., Christensen K. D., Petersen C. M. Oral and intravenous acyclovir are equally effective in herpes zoster. J Antimicrob Chemother. 1984 Aug;14(2):185–189. doi: 10.1093/jac/14.2.185. [DOI] [PubMed] [Google Scholar]
  8. Peterslund N. A., Seyer-Hansen K., Ipsen J., Esmann V., Schonheyder H., Juhl H. Acyclovir in herpes zoster. Lancet. 1981 Oct 17;2(8251):827–830. doi: 10.1016/s0140-6736(81)91102-8. [DOI] [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES